Atrial fibrillation (AF) is associated with a risk of thromboembolic stroke and when this risk exceeds 1% per annum, long-term oral anticoagulation is generally advised. Symptomatic AF may be managed by left atrial ablation, and during the procedure, and afterwards the thromboembolic stroke rate is increased. The increased intra-procedural risk is addressed with the use of intravenous unfractionated heparin, and the short-term elevated risk, no longer than 8 weeks, requires maintenance of effective oral anticoagulation.
Atrial fibrillation (AF) is associated with a risk of thromboembolic stroke and when this risk exceeds 1% per annum, long-term oral anticoagulation is generally advised. Symptomatic AF may be managed by left atrial ablation, and during the procedure, and afterwards the thromboembolic stroke rate is increased. The increased intra-procedural risk is addressed with the use of intravenous unfractionated heparin, and the short-term elevated risk, no longer than 8 weeks, requires maintenance of effective oral anticoagulation. 1 During the ablation procedure itself, it was felt imprudent to continue oral anticoagulation because of concern relating to possible perforation of the vasculature or myocardium resulting in uncontrollable haemorrhage. Up until the last few years most patients with at-risk AF were treated with a vitamin K antagonist (VKA) oral anticoagulant (OAC). Their relatively long clinical effectiveness after stopping treatment meant that they had to be discontinued at least 5 days prior to an ablation procedure, and the intervening period could be bridged using a short-acting, low molecular weight heparin. However, when bridging was compared with continuous anticoagulation regimens, it was found to be associated with more adverse bleeding events than continuing VKA therapy, 2 and clinical practice consequently changed. Oral anticoagulation was continued throughout the procedure, often targeting the lower half of the therapeutic INR range (2.0-2.5). Direct oral anticoagulants (DOACs) have replaced VKAs for antithrombotic protection in many patients with AF, 4 and clinicians rapidly began to apply the same principles to DOAC anticoagulant cover for ablation procedures. There had been some experience with this approach in the Phase III pivotal clinical trials, 5 but the information was far from sufficient. Observational studies were also reported, but specifically designed randomized studies were needed. The first of these studies was VENTURE-AF in which patients were allocated to conventional vitamin K anticoagulation or therapy with rivaroxaban. 6 The study was far too small to provide statistically significant results but the findings did not raise any concerns. The RE-CIRCUIT study was then completed and recently reported. 7 Six hundred and seventy-eight patients were randomized to warfarin (INR 2.0-3.0) or uninterrupted dabigatran 150 mg bid therapy, and 338 patients in each group received anticoagulant treatment. Of the dabigatran-treated patients, 317 underwent ablation, and 318 patients treated with warfarin were ablated. The baseline characteristics of both groups were very similar. The results were compelling: 5 dabigatran (1.6%) and 22 warfarin-treated patients (6.9%) had major bleeds. The absolute risk difference was 5.3% (95% confidence interval -8.4 to 2.2, P = 0.0009) and the relative risk reduction was 77.2%. There were no strokes or thromboembolic events, other than one transient ischaemic attack (TIA) in the warfarin-treated group. Serious adverse events occurred more commonly with warfarin treatment, although more patients discontinued dabigatran, mostly for gastrointestinal intolerance. This study demonstrated significant superiority of a DOAC over a VKA OAC, although the statistical significance of the result might well have been due to the higher than usual major bleeding event rate seen with warfarin. Nevertheless, the event rates with dabigatran were very small, well within the clinical comfort zone. In addition, there is now an approved rapid reversal agent, idarucizumab available to counteract the anticoagulant effect of dabigatran. 8 The cardiac electrophysiologist can now feel confident that the patient may be safely continued with an anticoagulant throughout a left atrial ablation procedure, and if uncontrollable haemorrhage occurs it can be readily staunched using a highly effective reversal agent. Evidence already available supports the use of uninterrupted DOAC therapy throughout a left atrial ablation procedure, although it should be emphasized that the supporting trials involved experienced operators working in established centres with high volumes. Less experienced operators should not take these results to justify a less than very careful approach to performing these procedures under full anticoagulation. However, continuing with the therapy on which the patient has already started is preferable to changing to a VKA, simply because of prior experience and the mistaken assumption that this form of anticoagulation can be readily reversed. The wide availability of a rapid reversal agent for dabigatran strongly supports the use of this drug, especially in those that are started on an anticoagulant specifically because of a forthcoming ablation procedure.
